Orakl Oncology

Executive Summary

Orakl Oncology, founded in 2020 and headquartered in Paris, is an AI-native predictive platform company revolutionizing oncology drug discovery and development. The company integrates patient-derived biology with advanced artificial intelligence to accelerate and de-risk the creation of new cancer treatments. By leveraging a proprietary platform that models tumor biology and drug responses, Orakl aims to significantly reduce the time and cost associated with traditional drug development while improving success rates. As a private, early-stage biotech, Orakl is positioning itself at the intersection of AI and oncology, a rapidly growing field attracting substantial investment and partnership interest. The company's focus on predictive modeling addresses a critical bottleneck in oncology: the high failure rate of drug candidates in clinical trials. Orakl's platform enables researchers to identify the most promising compounds and patient populations earlier, potentially increasing the probability of clinical and commercial success. With no disclosed funding to date, Orakl is likely preparing for its initial institutional fundraising or seeking strategic collaborations to advance its technology and expand its capabilities. The company's location in France's burgeoning biotech hub provides access to talent and research infrastructure, supporting its mission to transform cancer treatment.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round60% success
• Q4 2026Pharmaceutical Partnership or Licensing Deal40% success
• Q3 2026Publication of Platform Validation Data in Peer-Reviewed Journal50% success